Methods and systems for the efficient and systematic identification of the repertoire of T-cell epitopes.

This invention relates to the rapid determination of the viral titer by contacting a solution comprising viral particles, such as lentiviral particles, comprising a heterologous envelope protein, such as VSV-G, with an immobilised receptor that binds to the envelope protein, and determining the binding of the viral particles to be immobilised receptor using surface plasmon resonance (SPR).

The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.

The subject invention pertains to materials and methods for detecting, preventing and treating retroviral infections in humans and other animals susceptible to infection by retrovirus. It has been discovered that FIV can be transmitted from cats to humans and that the FIV can infect human cells in vivo and that antibodies generated by the infected person cross-react with HIV antigens. Thus, the methods and compositions of the subject invention can be used to detect, prevent and treat FIV infection in humans and other non-feline animals that are susceptible to FIV infection. The methods and compositions of the invention can also be used to prevent and treat infection by HIV in humans.

Pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase. Compositions or kits comprising the pseudotyped lentiviral vector particles and a mammalian cell expressing an Angiotensin-converting Enzyme 2 (ACE2) protein. Methods of assaying for the presence of neutralizing antibodies against a SARS-CoV-2 S protein in a sample comprising antibodies by providing pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein and comprising a heterologous polynucleotide that encodes a label or a recombinase; providing mammalian cells expressing an ACE2 protein; contacting the mammalian cells expressing the ACE2 protein with the pseudotyped lentiviral vector particles bearing a SARS-CoV-2 S protein in the presence of a sample comprising antibodies; and assaying for the presence of a label in the mammalian cells.

Methods and kits for quantifying a viral species are presently claimed and described. The method includes the steps of preparing at least one labeled viral protein component by incubating a detectable dye with a virial species in the presence of sodium dodecyl sulfate (SDS); loading the labeled viral protein component onto a capillary electrophoresis (CE) capillary, wherein the CE capillary is filled with a buffer comprising a polymer matrix; applying a separation voltage to the CE capillary; detecting at least one labeled viral protein component with a detector, thereby producing a corresponding set of values; and quantifying a protein of interest in the viral protein component using the corresponding set of values.

A method of characterizing a lentivirus, comprising: providing a sample comprising a lentivirus population comprising a fully loaded lentivirus, a partially loaded lentivirus, and/or an empty lentivirus; contacting a substrate with the sample to capture the lentivirus population; contacting the captured lentivirus population with a first fluorescent agent comprising a first fluorescent label and a first binding molecule that binds an envelope protein of the lentivirus, a second fluorescent agent comprising a second fluorescent label and a second binding molecule that binds a capsid protein of the lentivirus, and a third fluorescent agent comprising a third fluorescent label that binds a payload; illuminating the captured lentivirus population with light to excite the fluorescent agents; detecting fluorescent lights emitted from the fluorescent agents at different wavelengths; and characterizing the lentivirus according to the detected fluorescent lights.

Provided herein are compositions and methods for detection of detection and treatment of Mycoplasma haemofelis and Mycoplasma haemocanis.

The present invention relates to a use of a protein nanoparticle-based hydrogel, and more particularly, to a use of a protein nanoparticle-based hydrogel capable of highly sensitive and simultaneous multi-detection of disease markers by using a hydrogel within which protein nanoparticles presenting multiple copies of disease marker detection probes are immobilized.

Methods and systems for the efficient and systematic identification of the repertoire of T-cell epitopes.